Cartesian Therapeutics, Inc.
RNAC
Clasificación en acciones
#18194
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides... Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Precio por acción
$6.44
Última sincronización: 2026-10-21
Capitalización bursátil
$194.84M
Cambio (1 día)
0.70%
Cambio (1 año)
865.08%
País
US
Comercio Cartesian Therapeutics, Inc. (RNAC)
Categoría
Healthcare
Historial del precio de la acción de Cartesian Therapeutics, Inc. (RNAC)
Precio más alto de cierre: $0.79 el 2023-12-01
Precio más bajo de cierre: $14.00 el 2016-06-01
Precio más bajo de cierre: $14.00 el 2016-06-01
Historial del precio de la acción de Cartesian Therapeutics, Inc. desde 2016 hasta 2026
Desempeño anual del precio de la acción
| Año | Rendimiento |
|---|---|
| 2023 | -33.64% |
| 2022 | -62.77% |
| 2021 | 0.01% |
| 2020 | 73.71% |
| 2019 | -58.81% |
| 2018 | -55.20% |
| 2017 | -51.08% |
| 2016 | 0.00% |
Precio de la acción de empresas similares o competidoras
| Empresa | Precio de la acción | Cambio 1a% | País |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.16 | -4.25% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
